Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy
This year’s ESMO congress will present new late-breaking data for doublet immune therapy for patients with localized renal cell carcinoma. This may give hope to extending the time patients live without recurrence.